JP2006249085A - プラットホーム抗体組成物 - Google Patents

プラットホーム抗体組成物 Download PDF

Info

Publication number
JP2006249085A
JP2006249085A JP2006056870A JP2006056870A JP2006249085A JP 2006249085 A JP2006249085 A JP 2006249085A JP 2006056870 A JP2006056870 A JP 2006056870A JP 2006056870 A JP2006056870 A JP 2006056870A JP 2006249085 A JP2006249085 A JP 2006249085A
Authority
JP
Japan
Prior art keywords
antibody
composition
millimolar
human
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006056870A
Other languages
English (en)
Japanese (ja)
Inventor
Tapan Kanti Das
カンティ ダス タパン
Kevin King
キング ケビン
Sandeep Nema
ネマ サンディープ
Satish Kumar Singh
クマー シング サティシュ
David Ethan Steinmeyer
イーサン スタインマイヤー デイビッド
David Li Zeng
リ ゼン デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Publication of JP2006249085A publication Critical patent/JP2006249085A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
JP2006056870A 2005-03-08 2006-03-02 プラットホーム抗体組成物 Pending JP2006249085A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65976605P 2005-03-08 2005-03-08
US72816505P 2005-10-19 2005-10-19
US75271205P 2005-12-20 2005-12-20
US76245606P 2006-01-26 2006-01-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012240979A Division JP2013032387A (ja) 2005-03-08 2012-10-31 プラットホーム抗体組成物

Publications (1)

Publication Number Publication Date
JP2006249085A true JP2006249085A (ja) 2006-09-21

Family

ID=36646098

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2006056870A Pending JP2006249085A (ja) 2005-03-08 2006-03-02 プラットホーム抗体組成物
JP2006056818A Pending JP2006249084A (ja) 2005-03-08 2006-03-02 抗ＭａｄＣＡＭ抗体組成物
JP2006056813A Pending JP2006249083A (ja) 2005-03-08 2006-03-02 抗ｍ−ｃｓｆ抗体組成物
JP2006056701A Expired - Lifetime JP5670004B2 (ja) 2005-03-08 2006-03-02 抗ｃｔｌａ−４抗体組成物
JP2012115478A Pending JP2012167120A (ja) 2005-03-08 2012-05-21 抗ｃｔｌａ−４抗体組成物
JP2012240979A Withdrawn JP2013032387A (ja) 2005-03-08 2012-10-31 プラットホーム抗体組成物
JP2015042425A Expired - Lifetime JP6212509B2 (ja) 2005-03-08 2015-03-04 抗ｃｔｌａ−４抗体組成物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2006056818A Pending JP2006249084A (ja) 2005-03-08 2006-03-02 抗ＭａｄＣＡＭ抗体組成物
JP2006056813A Pending JP2006249083A (ja) 2005-03-08 2006-03-02 抗ｍ−ｃｓｆ抗体組成物
JP2006056701A Expired - Lifetime JP5670004B2 (ja) 2005-03-08 2006-03-02 抗ｃｔｌａ−４抗体組成物
JP2012115478A Pending JP2012167120A (ja) 2005-03-08 2012-05-21 抗ｃｔｌａ−４抗体組成物
JP2012240979A Withdrawn JP2013032387A (ja) 2005-03-08 2012-10-31 プラットホーム抗体組成物
JP2015042425A Expired - Lifetime JP6212509B2 (ja) 2005-03-08 2015-03-04 抗ｃｔｌａ−４抗体組成物

Country Status (27)

Country Link
US (5) US20090238820A1 (https=)
EP (6) EP1865986B1 (https=)
JP (7) JP2006249085A (https=)
KR (2) KR100989280B1 (https=)
CN (1) CN103861102A (https=)
AR (4) AR053026A1 (https=)
AU (2) AU2006220829C1 (https=)
BE (1) BE2023C529I2 (https=)
BR (2) BRPI0608815B1 (https=)
CA (4) CA2600836A1 (https=)
CY (2) CY1121254T1 (https=)
DK (2) DK1865986T3 (https=)
ES (2) ES2569409T3 (https=)
FI (1) FIC20230027I1 (https=)
FR (1) FR23C1029I2 (https=)
HU (3) HUE041802T2 (https=)
IL (3) IL185380A0 (https=)
LT (2) LT2620450T (https=)
LU (1) LUC00312I2 (https=)
MX (2) MX2007010970A (https=)
NL (1) NL301240I2 (https=)
NZ (2) NZ561137A (https=)
PL (1) PL2620450T3 (https=)
PT (1) PT2620450T (https=)
SI (2) SI1865986T1 (https=)
TW (4) TW200719913A (https=)
WO (4) WO2006096461A2 (https=)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505942A (ja) * 2006-10-09 2010-02-25 デウン カンパニー，リミテッド 上皮細胞増殖因子を含有する安定な口内炎治療用液状組成物
JP2010508352A (ja) * 2006-11-01 2010-03-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低ｐＨおよび二価カチオンを用いる生物高分子を単離する方法
JP2011526880A (ja) * 2007-07-06 2011-10-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
JP2012502976A (ja) * 2008-09-19 2012-02-02 ファイザー・インク 安定な液体抗体配合物
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
JP2012511540A (ja) * 2008-12-10 2012-05-24 ノバルティス アーゲー 抗体製剤
JP2012533548A (ja) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
JP2015143238A (ja) * 2015-02-27 2015-08-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 抗体処方
JP2015205883A (ja) * 2008-09-12 2015-11-19 ライナット ニューロサイエンス コーポレイション Ｐｃｓｋ９拮抗薬
US9487581B2 (en) 2005-03-08 2016-11-08 Pfizer Inc. Anti-CTLA-4 antibody compositions
JP2017071627A (ja) * 2008-06-20 2017-04-13 ノバルティス アーゲー 凝集が低減された免疫グロブリン
JP2018502910A (ja) * 2014-12-22 2018-02-01 ノバルティス アーゲー Ｉｌ−１７抗体の医薬製品および安定した液体組成物
JP2019512540A (ja) * 2016-03-10 2019-05-16 ユーシービー バイオファーマ エスピーアールエル 医薬製剤
JP2021533163A (ja) * 2018-08-07 2021-12-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物
JP2023055780A (ja) * 2007-12-27 2023-04-18 中外製薬株式会社 高濃度抗体含有溶液製剤

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2949290B2 (ja) 1989-07-26 1999-09-13 京セラ株式会社 アモルファスシリコン系半導体膜の製法
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
EP1937306B1 (en) * 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
MX2009003306A (es) * 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
AU2012200284B2 (en) * 2006-10-06 2014-03-06 Amgen Inc. Stable Antibody Formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
EP2167127A1 (en) * 2007-07-10 2010-03-31 F. Hoffmann-Roche AG Novel formulation
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
JP5769969B2 (ja) * 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
ES2531385T3 (es) * 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CA2759836A1 (en) 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
BR112012004054B1 (pt) 2009-10-01 2021-09-08 F. Hoffmann-La Roche Ag Método para produzir um anticorpo anti-her2
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
EP3326645B1 (en) 2010-10-25 2020-03-18 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
JP5458188B2 (ja) * 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
DK2734547T3 (en) 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
US20130064811A1 (en) * 2011-09-09 2013-03-14 International Business Machines Corporation Methods to Enhance Cancer Treatment
CA2861402C (en) * 2012-01-30 2021-10-12 Guy Casy Stabilized aqueous antibody compositions
EA201590061A1 (ru) * 2012-06-21 2015-05-29 Юсб Фарма С.А. Фармацевтическая композиция
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
CN111973484A (zh) * 2013-03-12 2020-11-24 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
AU2014229282B2 (en) * 2013-03-15 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
EA031471B1 (ru) 2013-04-12 2019-01-31 МорфоСис АГ Антитела, направленные на m-csf
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN107108715A (zh) 2014-10-24 2017-08-29 默沙东公司 胰高血糖素和glp‑1受体的共激动剂
CN104357394B (zh) * 2014-10-24 2017-03-22 杭州阿诺生物医药科技股份有限公司 一种自体外周血淋巴细胞dc‑cik的培养方法
CN105669867A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗gitr/ctla-4双特异性抗体及其制备方法和用途
CA2916283C (en) 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
KR20250004095A (ko) 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2016183469A1 (en) * 2015-05-13 2016-11-17 Robert Kirken Anti-ctla-4 blockade
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX2018003298A (es) * 2015-09-22 2018-06-20 Pfizer Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
MA43587A (fr) * 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CN105777858B (zh) * 2016-03-22 2019-09-10 东软威特曼生物科技(南京)有限公司 多种抗体的复合稳定剂及其使用方法
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017189433A1 (en) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CN106432499A (zh) * 2016-11-24 2017-02-22 上海美迪西生物医药股份有限公司 Ctla‑4抗体fab在昆虫表达系统中的制备方法
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
GB201703062D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用
JP2020518598A (ja) * 2017-05-02 2020-06-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US20210187023A1 (en) * 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
EP3652211A1 (en) 2017-07-14 2020-05-20 Pfizer Inc. Antibodies to madcam
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
US11324774B2 (en) 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
AU2019329703B2 (en) 2018-08-26 2022-12-15 Attain Health Inc. Methods and compositions to increase hair growth and/or prevent hair loss
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
BR112021008060A2 (pt) * 2018-10-31 2021-11-23 Bioatla Inc Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
RU2754760C2 (ru) 2019-04-02 2021-09-07 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция анти-il17a антитела и ее применение
BR112021023345A2 (pt) * 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
TW202126329A (zh) 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
JP2023500775A (ja) * 2019-09-23 2023-01-11 メルク・シャープ・アンド・ドーム・エルエルシー 宿主細胞タンパク質が減少し、ポリソルベート－８０安定性が増加した、抗ｃｔｌａ４モノクローナル抗体を含む方法および組成物
US20230035617A1 (en) * 2019-11-13 2023-02-02 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation
EP4082572A4 (en) * 2019-12-25 2024-03-06 Bio-Thera Solutions, Ltd. ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD AND ITS APPLICATION
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
JP2023537316A (ja) * 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
TWI907491B (zh) * 2020-08-26 2025-12-11 美商健生生物科技公司 包括雙特異性egfr/c-met抗體之穩定調配物
US20230366043A1 (en) * 2020-10-06 2023-11-16 Materials and Machines Corporation of America Method for detection of rna or dna from bological samples
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
CN116601295A (zh) * 2020-12-03 2023-08-15 江苏恒瑞医药股份有限公司 一种抗tslp抗体药物组合物及其用途
CN112569183B (zh) * 2020-12-11 2022-12-09 上海赛金生物医药有限公司 一种抗ctla-4抗体及融合蛋白的制剂
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
KR20250099736A (ko) * 2022-11-04 2025-07-02 아스트라제네카 아베 항-ctla 항체 조성물 및 관련 방법
WO2024110868A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited DOSAGE REGIMEN OF MAdCAM-1 ANTIBODY FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
AU2024231648A1 (en) * 2023-03-09 2025-09-04 Merck Sharp & Dohme Llc Formulations comprising actriia protein variants
WO2024262576A1 (ja) 2023-06-20 2024-12-26 国立大学法人 東京大学 免疫刺激型ヘルペスウイルス
CN117554633A (zh) * 2023-11-14 2024-02-13 四川沃文特生物技术有限公司 一种用于测定prl催乳素的检测试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05178719A (ja) * 1991-12-26 1993-07-20 Kanebo Ltd 抗体の安定化方法及び水性組成物ならびに化粧料
JP2002504907A (ja) * 1997-06-13 2002-02-12 ジェネンテク，インコーポレイテッド 抗体製剤
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
JP2004538287A (ja) * 2001-07-25 2004-12-24 プロテイン デザイン ラブス インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
RU1438240C (ru) 1987-04-22 1996-03-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК РТNF 22, СОДЕРЖАЩАЯ ПОЛУСИНТЕТИЧЕСКИЙ ГЕН ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА - ПРОМЕЖУТОЧНАЯ ПЛАЗМИДА ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 31, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH0595794A (ja) * 1991-10-04 1993-04-20 Otsuka Pharmaceut Co Ltd ヒトｍ−ｃｓｆ抗体及びヒトｍ−ｃｓｆの測定法
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU685784B2 (en) 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
BR0206455A (pt) * 2001-11-15 2004-01-13 Koninkl Philips Electronics Nv Método e dispositivo de gravação de portador de gravação
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
CN1703233A (zh) * 2002-07-12 2005-11-30 米德列斯公司 防止蛋白氧化降解的方法和组合物
DE60332483D1 (de) * 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
AR054428A1 (es) * 2005-03-08 2007-06-27 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
CN101227923A (zh) * 2005-07-08 2008-07-23 辉瑞有限公司 抗-MAdCAM抗体在治疗腹部疾病及热带口炎性腹泻中的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05178719A (ja) * 1991-12-26 1993-07-20 Kanebo Ltd 抗体の安定化方法及び水性組成物ならびに化粧料
JP2002504907A (ja) * 1997-06-13 2002-02-12 ジェネンテク，インコーポレイテッド 抗体製剤
JP2004538287A (ja) * 2001-07-25 2004-12-24 プロテイン デザイン ラブス インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011044301; ＳＨＩＭＡＳＡＫＩ，Ａ．Ｋ．　ｅｔ　ａｌ: Ｃｌｉｎｉｃａ　ｃｈｉｍｉｃａ　ａｃｔａ Ｖｏｌ．２９９，　Ｎｏ．１-２, 2000, ｐ．１１９-２８ *
JPN6011044304; ＣＨＥＮ，Ｂ．　ｅｔ　ａｌ: Ｐｈａｒｍａｃｅｕｔｉｃａｌ　ｒｅｓｅａｒｃｈ Ｖｏｌ．２０，　Ｎｏ．１２, 2003, ｐ．１９５２-６０ *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487581B2 (en) 2005-03-08 2016-11-08 Pfizer Inc. Anti-CTLA-4 antibody compositions
JP2010505942A (ja) * 2006-10-09 2010-02-25 デウン カンパニー，リミテッド 上皮細胞増殖因子を含有する安定な口内炎治療用液状組成物
US9155697B2 (en) 2006-10-09 2015-10-13 Daewoong Co., Ltd. Stable liquid compositions for treating stomatitis comprising epidermal growth factor
JP2010508352A (ja) * 2006-11-01 2010-03-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低ｐＨおよび二価カチオンを用いる生物高分子を単離する方法
JP2011526880A (ja) * 2007-07-06 2011-10-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
JP7605869B2 (ja) 2007-12-27 2024-12-24 中外製薬株式会社 高濃度抗体含有溶液製剤
JP7755720B2 (ja) 2007-12-27 2025-10-16 中外製薬株式会社 高濃度抗体含有溶液製剤
JP2023055780A (ja) * 2007-12-27 2023-04-18 中外製薬株式会社 高濃度抗体含有溶液製剤
JP7825771B2 (ja) 2007-12-27 2026-03-06 中外製薬株式会社 高濃度抗体含有溶液製剤
JP2025038054A (ja) * 2007-12-27 2025-03-18 中外製薬株式会社 高濃度抗体含有溶液製剤
JP2026004478A (ja) * 2007-12-27 2026-01-14 中外製薬株式会社 高濃度抗体含有溶液製剤
JP2017071627A (ja) * 2008-06-20 2017-04-13 ノバルティス アーゲー 凝集が低減された免疫グロブリン
JP2015205883A (ja) * 2008-09-12 2015-11-19 ライナット ニューロサイエンス コーポレイション Ｐｃｓｋ９拮抗薬
JP2012502976A (ja) * 2008-09-19 2012-02-02 ファイザー・インク 安定な液体抗体配合物
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
JP2012511540A (ja) * 2008-12-10 2012-05-24 ノバルティス アーゲー 抗体製剤
JP2018168158A (ja) * 2008-12-10 2018-11-01 ノバルティス アーゲー 抗体製剤
JP2015231997A (ja) * 2008-12-10 2015-12-24 ノバルティス アーゲー 抗体製剤
JP2020203889A (ja) * 2008-12-10 2020-12-24 ノバルティス アーゲー 抗体製剤
JP2023109938A (ja) * 2008-12-10 2023-08-08 ノバルティス アーゲー 抗体製剤
JP7286595B2 (ja) 2008-12-10 2023-06-05 ノバルティス アーゲー 抗体製剤
JP2012533548A (ja) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
JP2020011963A (ja) * 2014-12-22 2020-01-23 ノバルティス アーゲー Ｉｌ−１７抗体の医薬製品および安定した液体組成物
JP2018502910A (ja) * 2014-12-22 2018-02-01 ノバルティス アーゲー Ｉｌ−１７抗体の医薬製品および安定した液体組成物
JP2015143238A (ja) * 2015-02-27 2015-08-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 抗体処方
JP2022062014A (ja) * 2016-03-10 2022-04-19 ユーシービー バイオファーマ エスピーアールエル 医薬製剤
JP7539761B2 (ja) 2016-03-10 2024-08-26 ユーシービー バイオファーマ エスアールエル 医薬製剤
JP2019512540A (ja) * 2016-03-10 2019-05-16 ユーシービー バイオファーマ エスピーアールエル 医薬製剤
JP2024056774A (ja) * 2018-08-07 2024-04-23 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物
JP2021533163A (ja) * 2018-08-07 2021-12-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物

Also Published As

Publication number Publication date
LTPA2023522I1 (https=) 2023-09-11
DK1865986T3 (en) 2016-04-11
KR20070100922A (ko) 2007-10-12
EP2311491A1 (en) 2011-04-20
AU2006220829A1 (en) 2006-09-14
HUS2300026I1 (hu) 2023-09-28
AR054233A1 (es) 2007-06-13
CY2023018I2 (el) 2024-02-16
PL2620450T3 (pl) 2019-05-31
CA2600608A1 (en) 2006-09-14
CA2600588A1 (en) 2006-09-14
AR053553A1 (es) 2007-05-09
FIC20230027I1 (fi) 2023-08-02
BE2023C529I2 (https=) 2025-09-05
IL185380A0 (en) 2008-02-09
US9487581B2 (en) 2016-11-08
US20090130119A1 (en) 2009-05-21
KR100996801B1 (ko) 2010-11-25
SI1865986T1 (sl) 2016-05-31
KR100989280B1 (ko) 2010-10-20
WO2006096490A2 (en) 2006-09-14
LUC00312I2 (https=) 2025-02-03
JP2012167120A (ja) 2012-09-06
HK1125297A1 (en) 2009-08-07
WO2006096491A3 (en) 2007-03-29
EP1871806A2 (en) 2008-01-02
MX2007010970A (es) 2007-09-19
ES2707284T3 (es) 2019-04-03
TW200719913A (en) 2007-06-01
NZ561137A (en) 2011-09-30
PT2620450T (pt) 2018-12-17
WO2006096461A2 (en) 2006-09-14
US20110027262A1 (en) 2011-02-03
CN103861102A (zh) 2014-06-18
EP2620450B1 (en) 2018-11-07
WO2006096461A3 (en) 2006-12-21
JP2013032387A (ja) 2013-02-14
WO2006096488A3 (en) 2006-11-30
TW200709817A (en) 2007-03-16
WO2006096491A9 (en) 2008-05-29
KR20070100848A (ko) 2007-10-11
EP2620450A2 (en) 2013-07-31
FR23C1029I1 (fr) 2023-10-06
JP2015110656A (ja) 2015-06-18
AR062247A1 (es) 2008-10-29
IL185483A (en) 2013-04-30
WO2006096491A2 (en) 2006-09-14
CA2600434C (en) 2017-09-19
TW200642694A (en) 2006-12-16
DK2620450T3 (en) 2019-02-04
AU2006220829B2 (en) 2011-10-13
SI2620450T1 (sl) 2019-01-31
BRPI0608855A2 (pt) 2010-02-02
AU2006220828A1 (en) 2006-09-14
TWI365747B (en) 2012-06-11
ES2569409T3 (es) 2016-05-10
HUE041802T2 (hu) 2019-05-28
EP1865986B1 (en) 2016-02-17
EP2620450A3 (en) 2014-01-08
CA2600836A1 (en) 2006-09-14
WO2006096490A8 (en) 2007-02-01
EP1868646A2 (en) 2007-12-26
BRPI0608815B1 (pt) 2021-10-13
IL185483A0 (en) 2008-01-06
LT2620450T (lt) 2019-02-11
US20080248047A1 (en) 2008-10-09
NZ560844A (en) 2008-08-29
JP6212509B2 (ja) 2017-10-11
JP2006249083A (ja) 2006-09-21
EP1865986A2 (en) 2007-12-19
LTC2620450I2 (https=) 2024-11-11
AR053026A1 (es) 2007-04-18
FR23C1029I2 (fr) 2024-06-14
CA2600434A1 (en) 2006-09-14
US20090110681A1 (en) 2009-04-30
JP2006249084A (ja) 2006-09-21
JP2006249081A (ja) 2006-09-21
IL225435A0 (en) 2013-06-27
BRPI0608815A8 (pt) 2017-03-21
MX2007010971A (es) 2007-09-19
NL301240I2 (nl) 2025-07-31
AU2006220829C1 (en) 2025-01-02
EP1858552A2 (en) 2007-11-28
CY2023018I1 (el) 2023-11-15
WO2006096490A3 (en) 2006-12-28
US20090238820A1 (en) 2009-09-24
BRPI0608815A2 (pt) 2010-01-26
WO2006096488A2 (en) 2006-09-14
CY1121254T1 (el) 2020-05-29
JP5670004B2 (ja) 2015-02-18
HUE028410T2 (en) 2016-12-28
TW200700081A (en) 2007-01-01

Similar Documents

Publication Publication Date Title
JP2006249085A (ja) プラットホーム抗体組成物
CA2648882C (en) Humanized c-kit antibody
CA2962519C (en) Novel fully human anti-vap-1 monoclonal antibodies
CN101325968B (zh) 抗ctla-4抗体组合物
CN117015553A (zh) 包含白细胞介素-18结合蛋白和抗血清白蛋白的抗原结合片段的重组融合蛋白及其组合物和用途
AU2012200203B2 (en) Anti-CTLA-4 Antibody Compositions
RU2356579C1 (ru) Композиция антител против ctla-4
HK1187930A (en) Anti-ctla-4 antibody compositions
HK1125297B (en) Anti-ctla-4 antibody compositions

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070920

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090227

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121114

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20121122

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130104